541602 | Soy Extract Polar
Soybean Polar Lipid Extract
Soy Extract Polar
Soybean Polar Lipid Extract
- Phospholipid Profile
- Safety Data Sheet
- Safety Data Sheet
Zheng X, Fu Z, Su D, Zhang Y, Li M, Pan Y, Li H, Li S, Grassucci RA, Ren Z, Hu Z, Li X, Zhou M, Li G, Frank J, Yang J. Mechanism of ligand activation of a eukaryotic cyclic nucleotide-gated channel. Nat Struct Mol Biol. 2020 Jul;27(7):625-634. doi: 10.1038/s41594-020-0433-5. Epub 2020 Jun 1. PMID: 32483338; PMCID: PMC7354226.
PubMed ID: 32483338Deng Z, Maksaev G, Rau M, Xie Z, Hu H, Fitzpatrick JAJ, Yuan P. Gating of human TRPV3 in a lipid bilayer. Nat Struct Mol Biol. 2020 Jul;27(7):635-644. doi: 10.1038/s41594-020-0428-2. Epub 2020 Jun 22. PMID: 32572252; PMCID: PMC7354234.
PubMed ID: 32572252Wang Z, Hu W, Zheng H. Pathogenic siderophore ABC importer YbtPQ adopts a surprising fold of exporter. Sci Adv. 2020 Feb 5;6(6):eaay7997. doi: 10.1126/sciadv.aay7997. PMID: 32076651; PMCID: PMC7002159.
PubMed ID: 32076651Wang Z, Hu W, Zheng H. Pathogenic siderophore ABC importer YbtPQ adopts a surprising fold of exporter. Sci Adv. 2020 Feb 5;6(6):eaay7997. doi: 10.1126/sciadv.aay7997. PMID: 32076651; PMCID: PMC7002159.
PubMed ID: 32076651Berg J, Liu J, Svahn E, Ferguson-Miller S, Brzezinski P. Structural changes at the surface of cytochrome c oxidase alter the proton-pumping stoichiometry. Biochim Biophys Acta Bioenerg. 2020 Feb 1;1861(2):148116. doi: 10.1016/j.bbabio.2019.148116. Epub 2019 Nov 14.
PubMed ID: 31733183Rovini A, Gurnev PA, Beilina A, Queralt-Martín M, Rosencrans W, Cookson MR, Bezrukov SM, Rostovtseva TK. Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC. Cell Mol Life Sci. 2019 Nov 23. doi: 10.1007/s00018-019-03386-w. [Epub ahead of print]
PubMed ID: 31760463Lin King JV, Emrick JJ, Kelly MJS, Herzig V, King GF, Medzihradszky KF, Julius D. A Cell-Penetrating Scorpion Toxin Enables Mode-Specific Modulation of TRPA1 and Pain. Cell. 2019 Sep 5;178(6):1362-1374.e16. doi: 10.1016/j.cell.2019.07.014. Epub 2019 Aug 22.
PubMed ID: 31447178Cheng WWL, Budelier MM, Sugasawa Y, Bergdoll L, Queralt-Martín M, Rosencrans W, Rostovtseva TK, Chen ZW, Abramson J, Krishnan K, Covey DF, Whitelegge JP, Evers AS. Multiple neurosteroid and cholesterol binding sites in voltage-dependent anion channel-1 determined by photo-affinity labeling. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun 5;1864(10):1269-1279. doi: 10.1016/j.bbalip.2019.06.004. [Epub ahead of print]
PubMed ID: 31176038Baharan Ali Doosti, Weria Pezeshkian, Dennis S. Bruhn John H. Ipsen, Himanshu Khandelia, Gavin D. M. Jeffries, and Tatsiana Lobovkina Membrane Tubulation in Lipid Vesicles Triggered by the Local Application of Calcium Ions. Langmuir, Article ASAP
PubMed ID: 28910109- Certificate of Analysis(Lot No. 541602C-100MG-A-049and 5051CLA049)
- Certificate of Analysis(Lot No. 541602C-1G-A-049and 5051CQA049)
- Certificate of Analysis(Lot No. 541602C-500MG-A-049and 5051CPA049)
- Certificate of Analysis(Lot No. 541602P-100MG-A-049and 5051PLA049)
- Certificate of Analysis(Lot No. 541602P-1G-A-048and 5051PQA048)
- Certificate of Analysis(Lot No. 541602P-500MG-A-048and 5051PPA048)
- Certificate of Analysis(Lot No. 541602C-100MG-B-049and 5051CLB049)
- Certificate of Analysis(Lot No. 541602P-1G-A-050and 5051PQA050)
- Certificate of Analysis(Lot No. 541602C-500MG-A-050and 5051CPA050)
- Certificate of Analysis(Lot No. 541602P-500MG-A-050and 5051PPA050)
- Certificate of Analysis(Lot No. 541602P-100MG-A-050and 5051PLA050)
- Certificate of Analysis(Lot No. 541602P-1G-B-050and 5051PQB050)
- Certificate of Analysis(Lot No. 541602P-500MG-A-051and 5051PPA051)
- Certificate of Analysis(Lot No. 541602P-100MG-A-051and 5051PLA051)
- Certificate of Analysis(Lot No. 541602C-100MG-A-051and 5051CLA051)
- Certificate of Analysis(Lot No. 541602C-1G-A-051and 5051CQA051)
- Certificate of Analysis(Lot No. 541602C-100MG-B-051and 5051CLB051)
- Certificate of Analysis(Lot No. 541602C-500MG-A-051and 5051CPA051)
- Certificate of Analysis(Lot No. 541602P-1G-A-051and 5051PQA051)
- Certificate of Analysis(Lot No. 541602P-1G-A-052and 5051PQA052)
- Certificate of Analysis(Lot No. 541602C-500MG-A-052and 5051CPA052)
- Certificate of Analysis(Lot No. 541602C-100MG-A-052and 5051CLA052)
- Certificate of Analysis(Lot No. 541602C-100MG-B-052and 5051CLB052)
- Certificate of Analysis(Lot No. 541602C-1G-A-052and 5051CQA052)
- Certificate of Analysis(Lot No. 541602P-500MG-A-053and 5051PPA053)
- Certificate of Analysis(Lot No. 541602C-1G-B-052and 5051CQB052)
- Certificate of Analysis(Lot No. 541602P-100MG-A-053and 5051PLA053)
- Certificate of Analysis(Lot No. 541602C-100MG-C-052and 5051CLC052)
- Certificate of Analysis(Lot No. 541602P-500MG-A-052and 5051PPA052)
- Certificate of Analysis(Lot No. 541602P-100MG-B-053and 5051PLB053)
- Certificate of Analysis(Lot No. 541602C-1G-A-053and 5051CQA053)
- Certificate of Analysis(Lot No. 541602C-500MG-A-053and 5051CPA053)
- Certificate of Analysis(Lot No. 541602C-1G-B-053and 5051CQB053)
- Certificate of Analysis(Lot No. 541602C-100MG-A-053and 5051CLA053)
- Certificate of Analysis(Lot No. 541602C-500MG-B-053and 5051CPB053)
- Certificate of Analysis(Lot No. 541602C-500MG-C-053and 5051CPC053)
- Certificate of Analysis(Lot No. 541602C-100MG-C-053and 5051CLC053)
- Certificate of Analysis(Lot No. 541602P-1G-A-053and 5051PQA053)
- Certificate of Analysis(Lot No. 541602P-100MG-A-054and 5051PLA054)
- Certificate of Analysis(Lot No. 541602P-1G-B-054and 5051PQB054)
- Certificate of Analysis(Lot No. 541602C-100MG-C-054and 5051CLC054)
- Certificate of Analysis(Lot No. 541602C-500MG-A-056and 5051CPA056)
- Certificate of Analysis(Lot No. 541602C-1G-A-056and 5051CQA056)
- Certificate of Analysis(Lot No. 541602P-500MG-B-056and 5051PPB056)
- Certificate of Analysis(Lot No. 541602C-100MG-B-056and 5051CLB056)
- Certificate of Analysis(Lot No. 541602P-100MG-A-056and 5051PLA056)
- Certificate of Analysis(Lot No. 541602P-1G-B-056and 5051PQB056)
- Certificate of Analysis(Lot No. 541602 C 500 MG B 056and 5051 CPB056)
- Certificate of Analysis(Lot No. 541602 C 500 MG B 056and 5051 CPB056)
AvantiPolarLipids公司是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。 AvantiPolarLipids,Inc.,hasalonghistoryof50yearscreatingthehighestpuritylipidsavailable.Ourpassionforhighqualityanduniqueproductsisonlyexceededbyourexcellentreputationinthemarketplace. Althoughweareknownforourlipids,weareMorethanLipids.Weoffersolutionsfortheentireproductcycle…ResearchtoCommercialization. AvantiPolarLipids公司的主要产品和服务包括:(1)ResearchProductsHighestPurityLipidReagents(2)cGMPManufacturingAPI&ContractManufacturing(3)AdjuvantsImmunotherapy&VaccineDevelopment(4)AnalyticalServicesLipidAnalysis(5)LipidomicsMassSpecStandards,Antibodies&LipidToolbox(6)Formulationsliposomes&Nanoparticles(7)EquipmentLiposomeProductionTools(8)CustomServicesSynthesis&Beyond
AvantiPolarLipids是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至吨级的磷脂类和甾体类中间体和试剂。为世界范围内的研究机构和制药公司提供1000种以上脂类产品,由于其产品的高纯度而享誉全球。40年来,AvantiPolarLipids公司为世界各地的研究人员和制药公司提供脂类产品。公司的产品不仅范围日益扩大,其纯度之高也是无人能及。
AvantiPolarLipidsInc,是美国著名的磷脂类产品的生产商,该公司主要为各种制药厂和研究机构提供从毫克级到公斤级乃至百公斤级的磷脂类和甾体类中间体和试剂。主要产品Naturalsphingolipids天然鞘脂类Naturalphospholipids天然磷脂类Naturallipidsbyextraction天然提取脂类Referencestandards相关标准品Syntheticsphingolipids合成鞘脂类--Sphingosines&S-1-P鞘氨醇和鞘氨醇-1-磷酸盐--Ceramides神经酰胺--Sphingomyelins鞘磷脂--Sphingosine&ceramidederivatives鞘氨醇及神经酰胺衍生物--Sphinganine&derivatives鞘氨醇及其衍生物--C17sphingolipids十七碳鞘脂类--C20sphingolipids二十碳鞘脂类--Phytosphingosine&derivatives植物鞘氨醇及其衍生物Syntheticlipids&phospholipids合成脂质与磷脂--PC卵磷脂--PA磷脂酸--PE脑磷脂--PG磷脂酰甘油--PS磷脂酰丝氨酸--PI,PIP2&PIP3磷脂酰肌醇,磷脂酰肌醇-4,5-二磷酸,磷脂酰-3,4,5-三磷酸--CA胆酸--LysoPC溶源性卵磷脂--LysoPA溶源性磷脂酸--LysoPAAnalogues溶源性磷脂酸类似物--Lysobio-PA溶源性双磷脂酸--LysoPE,PG&PS溶源性脑磷脂,磷脂酰甘油和磷脂酰丝氨酸--AlkylPC烷基卵磷脂--Diether&Diphytanoyletherlipids二醚与二植烷醚脂质--PAF血小板活化因子--AcylPAFAnalog酰化血小板活化因子类似物--Brominatedphosphocholines溴代胆碱磷酸--Alkylphosphatederivatives烷基磷酸盐衍生物--Plasmalogen缩醛磷脂--Functionalizedlipids功能性脂类--Biotinylatedlipids生物素酰化脂质--Bioactivelipids生物活性脂类Syntheticphospholipids合成磷酸--AcylcoenzymeA乙酰辅酶A--Metabolicintermediates代谢中间产物--Adhesivelipid粘合脂质--pHsensitivelipids酸度计用脂质Transfectionreagents转染试剂Sterolderivatives甾酮衍生物Lipidblends混合脂质Glycosylatedphospholipids糖化磷脂Fluorinatedphospholipids氟化磷脂Chelators螯合剂Pre-mixedlipidsforbicelleformation构型分析用预混合脂质Diacylglycerols&analogues甘油二酯与类似物Deuteriumlabeledlipids氘标记脂质C13PC碳-13标记卵磷脂DoxylPC自旋标记卵磷脂TempoPCTempo(4-氧-4-羟-四甲基呱啶氮氧自由基)标记卵磷脂Fluoresecentsphingolipids荧光标记鞘脂类--Omegalabeled欧米加标记物--Fattyacidlabeled脂肪酸标记物Fluoresecentcholesterol荧光标记胆固醇Fluoresecentphospholipids荧光标记磷脂--Fattyacidlabeled脂肪酸标记物--Headgrouplabeled首基标记物Polymerizablelipids聚合脂质Poly(Ethyleneglycol)-lipidconjugates共轭聚脂质FunctionalizedPEGlipids功能PEG脂质Analyticalservices分析服务Drugdeliveryproduct药物运送载体Bulklipidsforpharmaceuticalproduction工业级脂质Equipment设备
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
为了帮助临床医师客观地了解NSAIDs,避开制药公司的导向以便更好地指导临床实践,本报请广州中山大学附属第一医院风湿免疫内科杨岫岩教授向读者介绍NSAIDs临床应用的一些问题。
NSAIDs的发展
从乙酰水杨酸(阿司匹林)应用至临床到现在,已经超过100个年头。1948年第一个非水杨酸类的NSAIDs保泰松问世后,抗炎镇痛药的种类迅速增加,如吲哚美辛、双氯芬酸、布洛芬、萘普生等,使NSAIDs“家族”迅速壮大。作为其“元老”的保泰松,虽然具有很强的抗炎镇痛作用,但潜在的严重副作用(再生障碍性贫血等)使其被淘汰。
1971年,环氧化酶(COX)理论解释了NSAIDs的作用机制。NSAIDs通过抑制COX,阻止花生四烯酸转变为前列腺素,后者既是炎症介质,又有生理功能。因此NSAIDs在抗炎镇痛的同时可引起胃肠道反应。20年后,研究者发现,COX存在不同的异构体,从而提出了COX异构体理论。认为COX存在两个异构体,一个是构建型的,称COX-1,以维持生理平衡为主;另一个是诱导型的称COX-2,主要参与炎症性前列腺素合成。
1994年,氟舒胺成为第一个被报道在实验室证实具有选择性COX-2抑制作用的NSAIDs,但在1996年III期临床试验总结时发现,该药具有肝毒性而未能获准上市。1995年Lancet上首先称萘丁美酮、美洛昔康、尼美舒利等为“选择性COX-2抑制剂”,虽然同年该期刊刊出几篇读者来信,对此提法提出争议,但是后来人们仍普遍接受这种提法。1999年,针对COX异构体理论研制的昔布类药物(塞来昔布和罗非昔布)上市,被称为“特异性COX-2抑制剂”。
虽然COX异构体理论尚需完善,但它的确是新型NSAIDs研制的一个突破口。除已经问世的昔布类药物外,新的昔布类Etoricoxib、parecoxib、valdecoxib也将投入临床。新研制的COX-2抑制剂不只限于昔布类,磺酰苯胺类也是研制新型COX-2抑制剂的方向,如氟舒胺、NS-398、HN-56249等。另外,针对COX和脂氧化酶(5-lipoxygenase
B、是重要的储能物质,磷脂为构成生物膜的重要成分,固醇为动物细胞膜的构成物质及形成激素等,B错误;
C、蛋白质是细胞代谢的主要结构物质,糖类是细胞代谢的主要能源物质C错误;
D、ATP的结构简式是 A-P~P~P,其中A代表腺苷,腺苷是构成ATP的重要部分,D正确.
故选:D.